Pseudotype Production Optimization

伪型生产优化

• 批准号: 6583151
• 负责人: Benjamin Jacob Doranz
• 金额: $ 45.48万
• 依托单位: INTEGRAL MOLECULAR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-02-15 至 2005-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6583151
• 关键词: Adenoviridae; G protein; Retroviridae; SDS polyacrylamide gel electrophoresis; biosensor device; cell membrane; drug discovery /isolation; enzyme linked immunosorbent assay; lipid bilayer membrane; membrane proteins; method development; protein binding; protein purification; protein structure function; receptor coupling; receptor expression; tissue /cell culture; transfection /expression vector; transmission electron microscopy

DESCRIPTION (provided by applicant): ViraCore is a tool-based biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotechnology industries. ViraCore is developing "lipoparticles", nanometer-sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structural integrity. ViraCore intends to leverage this technology for drug discovery and research of integral membrane proteins on biosensors and other microfluidic devices. Approximately half of the drugs in use today target membrane proteins, including G-protein coupled receptors. The purpose of this proposal is to scale lipoparticle production techniques, modify and improve lipoparticle properties, begin development of second-generation lipoparticles with unique capabilities, and validate lipoparticles for drug discovery applications. The goals of this proposal are to: - Optimize Commercial Manufacture Protocols - Develop Second- generation Lipoparticles - Improve Lipoparticle Composition - Validate Lipoparticles as Drug Screening Reagents

描述（由申请人提供）： Viracore是一家基于工具的生物技术公司，它正在创建一个药物发现平台，用于药物和生物技术行业。 Viracore正在开发“脂肪颗粒”，这是纳米大小的颗粒，周围是脂质双层，并嵌入了膜结合的受体，以纯化和溶解从细胞表面的复合受体，同时保持其结构完整性。 Viracore打算利用这项技术进行药物发现和对生物传感器和其他微流体设备上整体膜蛋白的研究。当今使用的大约一半的药物靶向膜蛋白，包括G蛋白偶联受体。该提案的目的是扩展脂肪生产技术，修改和改善脂质粒子特性，开始开发具有独特功能的第二代脂质颗粒，并验证用于药物发现应用的脂质粒子。该提案的目标是： - 优化商业制造方案 - 开发第二代脂质颗粒 - 改善脂质颗粒组成 - 验证脂肪颗粒作为药物筛查试剂